Physician profile
Michelle Baker
NPI 1255377545
$4,096.20
in general payments reported to CMS, 2019-2025
25 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $337 · 2023: $461 · 2024: $1,286 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $710.67 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $481.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $479.47 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.95 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $278.88 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $244.84 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $219.19 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $209.61 | 2022-2024 | Jornay Pm |
| Bausch Health US, LLC | $180.14 | 2023-2024 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $107.33 | 2021-2022 | |
| Lundbeck LLC | $106.60 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $94.41 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $94.34 | 2023-2025 | Wegovy |
| Axsome Therapeutics, INC. | $82.99 | 2024-2025 | Auvelity, Sunosi |
| Biogen, INC. | $81.98 | 2024-2025 | Leqembi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $59.66 | 2024 | |
| Vanda Pharmaceuticals INC. | $55.08 | 2023-2025 | Fanapt, Hetlioz |
| Acadia Pharmaceuticals INC | $40.35 | 2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $38.68 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $37.10 | 2024 | |
| Alfasigma USA, INC. | $31.59 | 2021 | |
| Corium, LLC | $25.14 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $18.89 | 2021 | |
| Almatica Pharma LLC | $18.10 | 2025 | Loreev Xr |
| Neos Therapeutics, LP | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.